BrightGene Bio-Medical Technology Co., Ltd. Stock: price and insider trades · China
博瑞医药
No insider purchase over the last 90 days. The latest, by 程增江, was filed 18 Nov 2024.
BrightGene Bio-Medical Technology Co., Ltd.: what insiders have been doing
Insider filings for BrightGene Bio-Medical Technology Co., Ltd. are scarce in the SSE / SZSE (CSRC) feed, the latest one published on 18 November 2024. This page will fill in as new trades are disclosed. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
Since the insiders bought
- +60.3%Entry CN¥31.65 · Close at T+365 CN¥50.75
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 3,000 shares100.0% of flowA股XSHGSSE:173000008276334900Canonical exit: 16 Feb 2025 (T+90)
1 of 1 declaration
About BrightGene Bio-Medical Technology Co., Ltd.
博瑞医药 is a company in the healthcare and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and commercialization of innovative drugs.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
